SUVALENT THERAPEUTICS INC. — Department of Health and Human Services SBIR Phase I: 102

Description

c Mycand KRas dependent cancerssuch as colorectal cancerrepresent major unmet medical needs that currently lack targeted therapyRecent scientific advances revealed that theseundruggableoncogenes critically depend on post translational modification with the small ubiquitin like modifierSUMOfamily of proteinsand inhibiting SUMOylation inhibits c Myc and KRasFurthermoreSUMOylation inhibition can activate anti tumor immune responsesGenomewide gene expression analysis has demonstrated that the SUMO activating enzymeEis the most overexpressed SUMOylation related protein in colorectal cancers tissuesSUMO Eoverexpression is also associated with cancer cell stemness and poor patient survivalThis evidence makes SUMO Ean attractive targetThereforewe propose to develop highly selectivepotentand orally available SUMO Einhibitors as targeted therapies for colorectal cancerUsing a high throughput screening campaignwe have identified a class of potent and specific SUMO Einhibitors suitable for development into orally available drugswhich could represent a new class of therapeutic agentsWe will conduct lead optimization of these compounds and validate the resulting candidates in cellular assays of colorectal cancerfollowed by pharmacokinetic and toxicity studiesIn addition to colorectal cancerwhich is the focus of our proposalinhibiting SUMOylation will likely inhibit other c Myc and KRas dependent cancersThusthe potent SUMO Einhibitors developed in the proposed studies are expected to have a major impact on cancer research and targeted therapy We propose to develop an orally available SUMO Einhibitor for cancer therapy